卵巢癌中MSI2蛋白表达及与临床病理特征的关系  

Expression of MSI2 protein in ovarian carcinoma and its correlation with clinicopathological factors

作　　者：甄娟[1] 刘玉东 宋春红[1] 吴莎 焦瑞芬 ZHEN Juan;LIU Yu-dong;SONG Chun-hong;WU Sha;JIAO Rui-fen(Department of Pathology,Shijiazhuang Fourth Hospital/Obstetrics and Gynecology Hospital Affiliated to Hebei Medical University,Shijiazhuang 050000,China;Department of Otolaryngology,Hebei General Hospital,Shijiazhuang 050057,China;Department of Obstetrics and Gynecology,Shijiazhuang Fourth Hospital/Obstetrics and Gynecology Hospital Affiliated to Hebei Medical University,Shijiazhuang 050000,China)

机构地区：[1]石家庄市第四医院/河北医科大学附属妇产医院病理科,石家庄050000 [2]河北省人民医院耳鼻咽喉科,石家庄050057 [3]石家庄市第四医院/河北医科大学附属妇产医院妇产科,石家庄050000

出　　处：《临床与实验病理学杂志》2022年第1期40-45,共6页Chinese Journal of Clinical and Experimental Pathology

基　　金：石家庄市科学技术研究与发展指导计划(171462003)。

摘　　要：目的探讨卵巢癌组织中RNA结合蛋白MSI2的表达及临床意义。方法采用免疫组化及Western blot法检测卵巢癌组织及配对癌旁正常卵巢组织和输卵管组织中MSI2的表达部位和表达量,分析MSI2表达与卵巢癌临床病理特征的关系。利用Kaplan-Meier生存曲线评估患者的总生存率,Cox回归模型分析MSI2表达的临床病理意义。结果与癌旁正常卵巢组织(16.00%)和输卵管组织(12.82%)相比,卵巢癌组织中MSI2的阳性率(73.33%)增高(P<0.001);与癌旁正常卵巢组织(0.38±0.06)和输卵管组织(0.33±0.08)相比,卵巢癌组织中MSI2的表达量(1.14±0.19)增高(P<0.001)。MSI2表达与Ⅱ型卵巢癌(P=0.021)、FIGO分期(P=0.003)及淋巴结转移(P=0.011)相关。MSI2阳性卵巢癌患者的总生存率低于MSI2阴性患者(P=0.003),MSI2蛋白表达水平是卵巢癌患者不良预后因素之一(P=0.031)。结论MSI2高表达可能在卵巢癌发生、发展中发挥重要作用,MSI2可能作为卵巢癌患者的预后生物学标志物。靶向MSI2可能为卵巢癌患者的治疗提供新的治疗策略。Purpose To investigate the expression and clinical significance of RNA-binding protein MSI2 in ovarian carcinoma.Methods The location and expression level of MSI2 in ovarian carcinoma and matched normal ovarian tissues and fallopian tube tissues were determined by immunohistochemical and Western blot assay,and the relationship between MSI2 protein and clinicopathologic factors was analyzed.The overall survival(OS)of patients was estimated using the Kaplan-Meier method,and Cox regression models was performed to investigate the clinicopathological significance of MSI2 expression.Results Compared with normal ovarian tissues(16.00%)and fallopian tubal tissues(12.82%),the positive rate of MSI2 in ovarian carcinoma tissues(73.33%)was increased(P<0.001).Compared with normal ovarian tissues(0.38±0.06)and fallopian tubal tissues(0.33±0.08),the relative expression of MSI2 in ovarian carcinoma tissues(1.14±0.19)was increased(P<0.001).The expression of MSI2 was significantly correlated with typeⅡovarian carcinoma(P=0.021),International Federation of Gynaecology and Obstetrics(FIGO)stage(P=0.003)and lymph node metastasis(P=0.011).Furthermore,patients with MSI2 positive expression exhibited significantly poorer OS(P=0.003)than patients with negative MSI2 expression.the level of MSI2 protein expression was an alternative predictor of poor prognosis in patients with ovarian carcinoma(P=0.031).Conclusion The overexpression of MSI2 plays an important role in the tumorigenesis and progression of ovarian carcinoma,and MSI2 may act as a prognostic biomarker in patients with ovarian carcinoma.Targeting MSI2 may therefore offer a promising therapeutic strategy for the treatment of patients with ovarian carcinoma.

关 键 词：卵巢肿瘤 MSI2 免疫组织化学 Western blot 预后 

分 类 号：R737.31[医药卫生—肿瘤]